In Depth 30 Nov 2023 Could an Alzheimer’s vaccine make treatment more affordable? Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […] November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Nov 2023 How are R&D Tax Incentives shaping Australia’s biotech future? Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […] November 27, 2023 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 23 Nov 2023 The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […] November 23, 2023 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […] November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff? Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA game? The Danish company, which […] November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […] November 16, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 15 Nov 2023 Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […] November 15, 2023 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 9 Nov 2023 Blood tests for Alzheimer’s: a hit or a miss? Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […] November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2023 The biggest private biotech investments in October 2023 The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […] November 6, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2023 How French pharma giant Sanofi is betting big on AI The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […] November 2, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2023 The ongoing search for an HIV cure: can CRISPR crack the code? HIV continues to represent a global health burden, with the World Health Organization (WHO) estimating that, in 2022, there were 39 million people living with the virus. But there is still no effective cure for it. The only option patients have is antiretroviral therapy, which, although it represents a major milestone in HIV treatment and […] October 30, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Oct 2023 Big pharma monopolies: major antitrust cases over the past decade Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby leading to a rise in […] October 27, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email